Heart Test Laboratories Stock Today
| HSCS Stock | USD 2.91 0.01 0.34% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Heart Test is selling for under 2.91 as of the 22nd of March 2025; that is 0.34 percent up since the beginning of the trading day. The stock's lowest day price was 2.84. Heart Test has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 15th of June 2022 | Category Healthcare | Classification Health Care |
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company was incorporated in 2007 and is headquartered in Southlake, Texas. Heart Test operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 1.08 M outstanding shares of which 37.4 K shares are currently shorted by private and institutional investors with about 1.7 trading days to cover. More on Heart Test Laboratories
Moving against Heart Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Heart Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Andrew Simpson | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHeart Test can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Heart Test's financial leverage. It provides some insight into what part of Heart Test's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Heart Test Laboratories (HSCS) is traded on NASDAQ Exchange in USA. It is located in 550 Reserve Street, Southlake, TX, United States, 76092 and employs 15 people. Heart Test is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.17 M. Heart Test Laboratories conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 1.08 M outstanding shares of which 37.4 K shares are currently shorted by private and institutional investors with about 1.7 trading days to cover.
Heart Test Laboratories currently holds about 4.27 M in cash with (6.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.52.
Check Heart Test Probability Of Bankruptcy
Ownership AllocationHeart Test retains 8.99 (percent) of its outstanding shares held by insiders and 0.15 (percent) owned by outside corporations.
Check Heart Ownership Details
Heart Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-12-31 | 1.3 K | |
| Oliver Lagore Vanvalin Investment Group | 2024-09-30 | 305 | |
| Tower Research Capital Llc | 2024-12-31 | 100.0 | |
| Bank Of America Corp | 8.0 | ||
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 0.0 | |
| Jpmorgan Chase & Co | 2024-12-31 | 0.0 | |
| Cultivar Capital Inc | 2024-09-30 | 0.0 | |
| Hrt Financial Llc | 2024-12-31 | 0.0 |
Heart Test Historical Income Statement
Heart Stock Against Markets
Heart Test Corporate Executives
Elected by the shareholders, the Heart Test's board of directors comprises two types of representatives: Heart Test inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heart. The board's role is to monitor Heart Test's management team and ensure that shareholders' interests are well served. Heart Test's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heart Test's outside directors are responsible for providing unbiased perspectives on the board's policies.
Additional Tools for Heart Stock Analysis
When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.